Lipopen (Ezetimibe, Rosuvastatin)

• Lipopen, a fixed‑dose combination of ezetimibe and rosuvastatin, is indicated for management of dyslipidemia and related lipid disorders.
• Hypercholesterolemia: lowers LDL‑cholesterol and total cholesterol to target levels.
• Mixed dyslipidemia: reduces triglycerides while modestly increasing HDL‑cholesterol.
• Primary hyperlipidemia: helps achieve recommended lipid goals to lower cardiovascular risk.

• Ezetimibe blocks the Niemann‑Pick C1‑like 1 (NPC1L1) transporter in the intestinal brush border, reducing dietary and biliary cholesterol absorption. Rosuvastatin competitively inhibits HMG‑CoA reductase in hepatocytes, decreasing endogenous cholesterol synthesis, up‑regulating LDL receptors and enhancing clearance of circulating LDL particles. The combined effect yields a synergistic reduction in plasma LDL‑cholesterol and overall atherogenic lipids.

Adverse reactions may occur with Lipopen and should be monitored.

Common Side Effects

• Headache
• Abdominal pain or discomfort
• Myalgia or muscle aches
• Diarrhea
• Nausea
• Elevated liver enzymes (ALT/AST)

Serious or Rare Side Effects

• Rhabdomyolysis or severe myopathy
• Acute liver injury or hepatitis
• Severe allergic reactions (rash, angioedema, anaphylaxis)
• Elevated creatine kinase levels
• Pancreatitis
• Thrombocytopenia

Before initiating therapy, clinicians should consider several safety aspects.

• Liver function monitoring: assess baseline transaminases and repeat periodically.
• Renal impairment: adjust therapy in patients with severe renal dysfunction.
• Drug interactions: review concomitant medications that affect CYP3A4 or statin metabolism.
• Pregnancy and lactation: avoid use unless benefits outweigh potential risks.
• Contraindications: do not use in active liver disease or unexplained persistent elevations of hepatic enzymes.
• Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Lipopen may interact with several medicines; awareness of interaction severity guides management.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., clarithromycin, itraconazole) – may increase rosuvastatin exposure.
• Cyclosporine – markedly raises rosuvastatin plasma levels.
• Gemfibrozil – raises risk of myopathy and rhabdomyolysis.

Moderate Interactions (Monitor Closely)

• Bile‑acid sequestrants – may reduce ezetimibe absorption; separate dosing by at least 2 hours.
• Other statins – additive risk of muscle toxicity; monitor CK.
• Anticoagulants (warfarin) – potential alteration of INR; check coagulation status.